

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Gumet Holding Co</u> (Last) (First) (Middle) C/O WAYPOINT INTERNATIONAL GP LLC 55 CAMBRIDGE PARKWAY, SUITE 401 (Street) CAMBRIDGE MA 02142 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/11/2018	3. Issuer Name and Ticker or Trading Symbol <u>Corium International, Inc. [CORI]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 10/22/2018 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value \$0.001 per share	0 ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾	I	N/A ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				

1. Name and Address of Reporting Person* <u>Gumet Holding Co</u> (Last) (First) (Middle) C/O WAYPOINT INTERNATIONAL GP LLC 55 CAMBRIDGE PARKWAY, SUITE 401 (Street) CAMBRIDGE MA 02142 (City) (State) (Zip)
--

1. Name and Address of Reporting Person* <u>Gumet Merger Sub, Inc.</u> (Last) (First) (Middle) C/O WAYPOINT INTERNATIONAL GP LLC 55 CAMBRIDGE PARKWAY, SUITE 401 (Street) CAMBRIDGE MA 02142 (City) (State) (Zip)
--

1. Name and Address of Reporting Person*

[Gumet Point, L.P.](#)

(Last) (First) (Middle)
C/O WAYPOINT INTERNATIONAL GP LLC
55 CAMBRIDGE PARKWAY, SUITE 401

(Street)
CAMBRIDGE MA 02142

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Waypoint International GP LLC](#)

(Last) (First) (Middle)
C/O WAYPOINT INTERNATIONAL GP LLC
55 CAMBRIDGE PARKWAY, SUITE 401

(Street)
CAMBRIDGE MA 02142

(City) (State) (Zip)

Explanation of Responses:

1. Gumet Holding Company ("Parent") and its direct wholly owned subsidiary, Gumet Merger Sub, Inc. ("Merger Sub"), entered into an Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), with Corium International, Inc. ("Corium"), pursuant to which Merger Sub will commence a tender offer (the "Offer") to purchase all of the issued and outstanding shares of Common Stock, par value \$0.001 per share, of Corium (the "Shares"), at a purchase price of \$12.50 per Share in cash, plus one non-transferable contingent value right for each share, which represents the contractual right to receive \$0.50 per Share following approval by the FDA of the New Drug Application for Corplex Donepezil, as described in and under the terms of the Contingent Value Rights Agreement (as described in the Merger Agreement), without interest. (Continued in Footnote 2)
2. Upon successful completion of the Offer, and subject to the terms and conditions of the Merger Agreement, Merger Sub will be merged with and into Corium with Corium surviving the Merger and becoming a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger Agreement, Parent and Merger Sub entered into a tender and support agreement, dated as of October 11, 2018 (the "Tender and Support Agreement"), with Essex Woodlands Health Ventures Fund VII, L.P., who agreed, subject to certain limited specified exceptions, to tender into the Offer, and not withdraw, all Shares owned of record or beneficially owned or acquired by them after such date (the "Subject Shares"), to vote the Subject Shares in favor of the Merger and vote against alternative acquisition proposals to the Merger and to refrain from disposing of the Subject Shares. (Continued in Footnote 3)
3. As of the date hereof, the Subject Shares include 9,353,304 Shares beneficially owned by Essex Woodlands Health Ventures Fund VII, L.P.
4. As Merger Sub is a direct wholly-owned subsidiary of Parent, and because Parent and Merger Sub executed the Tender and Support Agreement, and as a result of Parent being a direct wholly-owned subsidiary Gumet Point L.P. ("Gumet Point") and Waypoint International GP LLC being the general partner of Gumet Point ("Waypoint"), each of Parent, Merger Sub, Gumet Point and Waypoint (collectively, the "Reporting Persons") may be deemed to have acquired beneficial ownership over the Subject Shares for the purpose of determining its status as a ten percent holder thereof. However, as none of the Reporting Persons have any pecuniary interest in the Subject Shares, beneficial ownership over the Subject Shares is expressly disclaimed for reporting purposes.

Remarks:

Exhibit 99.1 (Joint Filer Information) is incorporated herein by reference. This amendment is being filed solely to add the EDGAR CIK of Waypoint International GP LLC. No other changes have been made to the Form 3 as originally filed on October 22, 2018.

/s/ James B. Singleton 10/22/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Exhibit 99.1 - Joint Filer Information

Designated Filer: Gurnet Holding Company
Issuer & Ticker Symbol: Corium International, Inc. (CORI)
Date of Event Requiring Statement: October 11, 2018

Joint Filers:

1. Name: Gurnet Holding Company

Address: c/o Waypoint International GP LLC
55 Cambridge Parkway, Suite 401
Cambridge, MA 02142

2. Name: Gurnet Merger Sub, Inc.

Address: c/o Waypoint International GP LLC
55 Cambridge Parkway, Suite 401
Cambridge, MA 02142

3. Name: Gurnet Point L.P.

Address: c/o Waypoint International GP LLC
55 Cambridge Parkway, Suite 401
Cambridge, MA 02142

4. Name: Waypoint International GP LLC

Address: 55 Cambridge Parkway, Suite 401
Cambridge, MA 02142

Exhibit 99.2 - Joint Filers' Signatures

Designated Filer: Gurnet Holding Company
Issuer & Ticker Symbol: Corium International, Inc. (CORI)
Date of Event Requiring Statement: October 11, 2018

GURNET HOLDING COMPANY

By:

/s/ James B. Singleton

Name: James B. Singleton

Title: Secretary

Date: October 22, 2018

GURNET MERGER SUB, INC.

By:

/s/ James B. Singleton

Name: James B. Singleton

Title: President

Date: October 22, 2018

GURNET POINT L.P.

By:

/s/ James B. Singleton

Name: James B. Singleton

Title: Manager of Waypoint International GP LLC, in its
capacity as General Partner of Gurnet Point L.P.

Date: October 22, 2018

WAYPOINT INTERNATIONAL GP LLC.

By:

/s/ James B. Singleton

Name: James B. Singleton

Title: Manager

Date: October 22, 2018
